Pregabalin Capsule
Product Images NDC 64980-417

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 64980-417). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin-100mg-1000-jpg (Pregabalin 100mg 1000)

Label for Pregabalin Capsules 100 mg by Rising Pharmaceuticals, Inc. This oral prescription drug comes in bottles of 1,000 capsules. The label includes storage instructions (20 to 25°C), manufacturer details including Laurus Labs Limited India, and a barcode. It specifies the product as Rx only.*

FDA Label Image

Pregabalin-150mg-1000-jpg (Pregabalin 150mg 1000)

Label for Pregabalin Capsules 150 mg by Rising Pharma Holdings, Inc. This oral capsule product is supplied in a large quantity package of 1,000 capsules. The label includes storage instructions, dispensing instructions, and manufacturing details by Laurus Labs Limited, India. The product is Rx only and the label shows the NDC 64980-414-10 with bar code.*

FDA Label Image

Pregabalin-200mg-1000-jpg (Pregabalin 200mg 1000)

Label for Pregabalin Capsules 200 mg by Rising Pharmaceuticals, Inc. The label indicates 1,000 capsules per container and includes storage instructions and dispensing information. Manufactured by Laurus Labs Limited in India, it also specifies the product is Rx only and must be dispensed with an accompanying Medication Guide.*

FDA Label Image

Pregabalin-225mg-1000-jpg (Pregabalin 225mg 1000)

Label for Pregabalin Capsules 225 mg by Rising Pharma Holdings, Inc. The label indicates 1,000 capsules in the container. It includes storage instructions, dispensing information, manufacturer details, and a barcode. The label notes the capsules contain 225 mg of pregabalin each and are prescription-only (Rx only).*

FDA Label Image

Pregabalin-25mg-1000-jpg (Pregabalin 25mg 1000)

Pregabalin 25 mg capsules label by Rising Pharmaceuticals showing a bottle containing 1,000 capsules. The label includes storage instructions, prescribing information note, manufacturer details (Laurus Labs Limited, India), and indicates the product is prescription only. The NDC code 64980-410-10 is displayed along with a barcode.*

FDA Label Image

Pregabalin-300mg-1000-jpg (Pregabalin 300mg 1000)

Label for Pregabalin Capsules 300 mg manufactured by Laurus Labs Limited and labeled by Rising Pharmaceuticals, Inc. The package contains 1,000 oral capsules with a prescription-only status. The label advises pharmacists to dispense the accompanying medication guide and includes storage instructions and manufacturer information.*

FDA Label Image

Pregabalin-50mg-1000-jpg (Pregabalin 50mg 1000)

Label for Pregabalin capsules 50 mg by Rising Pharma Holdings, Inc. The label indicates each capsule contains 50 mg of pregabalin and the package contains 1,000 capsules. It includes storage instructions, mentions the product is Rx only, and lists the manufacturer as Rising Pharmaceuticals, Inc. and Laurus Labs Limited. A barcode and space for lot and expiration dates are visible.*

FDA Label Image

Pregabalin-75mg-1000-jpg (Pregabalin 75mg 1000)

Label for Pregabalin Capsules, 75 mg strength, in a bottle containing 1,000 capsules. The label includes storage instructions and dosing information, states the capsules contain 75 mg of pregabalin each, and identifies Rising Pharmaceuticals, Inc. as the manufacturer and Laurus Labs Limited in India as the producer. It is marked Rx only and includes an NDC barcode.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure of pregabalin showing its molecular configuration including an amino group (NH2) and a carboxylic acid group (CO2H) attached to a carbon backbone.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula for calculating creatinine clearance (CLCr) based on age in years, weight in kilograms, serum creatinine levels in mg/dL, and an adjustment factor for female patients.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph depicting the percent of patients improved in relation to the percent improvement in pain from baseline for Pregabalin oral capsules at dosages of 25 mg, 100 mg, and 200 mg taken three times a day, compared to placebo. The x-axis represents the percent improvement in pain from baseline, while the y-axis shows the percent of patients improved.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline. It shows two curves representing Pregabalin 100 mg taken three times a day and placebo, with the Pregabalin group consistently demonstrating higher percentages of patient improvement across various pain improvement thresholds.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin capsules at 75 mg, 150 mg, and 300 mg doses taken twice daily, compared to placebo. The graph depicts higher patient improvement percentages with increasing doses of Pregabalin.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows greater improvement with Pregabalin doses compared to placebo over increasing pain improvement percentages.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. Three lines represent Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing comparative efficacy in pain improvement across different improvement percentages.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

A bar chart showing the responder rate (%) by treatment group in two clinical studies, Study E1 and Study E3, for Pregabalin at various doses and placebo. The x-axis lists placebo and different pregabalin doses, with the number of subjects per group indicated. The y-axis represents the responder rate percentage, with pregabalin groups generally showing higher responder rates than placebo. Statistically significant differences from placebo are noted.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line chart depicting seizure reduction as median percent change from baseline versus dose (mg/day) for Pregabalin from four studies labeled E1, E2, and E3 with dosings BD and TID. The chart shows significant p-values for various doses compared to placebo, illustrating dose-dependent seizure reduction effects in the studies.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 600 mg, 450 mg, 300 mg daily doses, and placebo. The graph compares patient improvement across different treatment groups, with percent improvement on the x-axis and percent of patients improved on the y-axis.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus placebo. The y-axis shows the estimated percentage of subjects without LTR, and the x-axis shows time in days. The Pregabalin group is represented by a solid line, and the placebo group by a dashed line, indicating a higher percentage of subjects without LTR in the Pregabalin group throughout the study period.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph comparing the percentage of subjects improved over time from baseline to week 12 measured in percent. It shows two lines: one solid line for Pregabalin and one dotted line for Placebo, illustrating greater improvement for Pregabalin across the range.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line graph comparing the percent of subjects improved from baseline to Week 16 using BOCF method. The x-axis shows the percent improved from 0 to 100, and the y-axis shows the percent of subjects improved. Two lines represent Pregabalin and Placebo groups, with Pregabalin showing consistently higher improvement percentages than Placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.